TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC

EP: 1.First-Line Treatment Strategies for Advanced Non–Small Cell Lung Cancer

EP: 2.The Role of CTLA-4 Inhibitors in NSCLC

EP: 3.NSCLC: PD-L1 Expression and Treatment Decision-Making

Now Viewing

EP: 4.TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC

EP: 5.Expert Perspectives on the Results of the TROPION-Lung01 Study in NSCLC

EP: 6.EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in Advanced NSCLC

EP: 7.TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC

EP: 8.A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC

EP: 9.First-Line Treatment for EGFR-Mutant Advanced Lung Cancer

EP: 10.FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

EP: 11.MARIPOSA: Amivantamab and Lazertinib in Frontline EGFR-Mutant NSCLC

EP: 12.Treatment Options in EGFR-Mutant NSCLC in Second Line and Beyond

EP: 13.MARIPOSA-2: Amivantamab and Chemotherapy in EGFR-Mutant NSCLC in Second Line and Beyond

EP: 14.Antibody-Drug Conjugates in EGFR-Mutant NSCLC

EP: 15.Clinical Pearls and Future Perspectives in Advanced NSCLC

This is a synopsis of a Peer Exchange video series featuring Benjamin P. Levy, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Solange Peters, MD, PhD, of University Hospital of Lausanne; Joshua K. Sabari, MD, of NYU Langone’s Perlmutter Cancer Center; Edward B. Garon, MD, MS, of UCLA Jonsson Comprehensive Cancer Center; and Marina Chiara Garassino, MD, of University of Chicago Medicine Comprehensive Cancer Center.

Dr Levy notes that while immunotherapy has improved first-line NSCLC [non–small cell lung cancer] outcomes, there remains only 1 approved second-line regimen: docetaxel with or without ramucirumab. Many trials have tried unsuccessfully to outperform docetaxel. Dr Peters concurs, stating recent failed trials with various immunotherapies and chemotherapies highlight docetaxel’s ongoing role as the second-line standard of care.

They discuss promising data from an abstract of the TROPION-Lung01 trial comparing the antibody-drug conjugate datopotamab deruxtecan to docetaxel in previously treated patients with NSCLC. Dr Peters explains the trial showed statistically significant improvement in progression-free survival from 3.7 to 4.4 months overall, and 3.7 to 5.6 months in the pre-planned non-squamous subgroup analysis. Response rate also nearly doubled from 13% to 26%. Toxicity profiles differ, but serious adverse events were lower with datopotamab deruxtecan.

In summary, Dr Peters feels these efficacy and toxicity findings support datopotamab deruxtecan as a new competitor to docetaxel in the second-line NSCLC setting that is likely to be adopted into clinical practice. Dr Levy agrees this is an important advance for patients progressing after first-line therapy.

*Video synopsis is AI-generated and reviewed by OncLive editorial staff.